公开(公告)号：KR1020150008807A

公开(公告)日：2015-01-23

申请号：KR1020140077026

申请日：2014-06-24

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  윤철호 ,  장지훈 ,  이화연 ,  오승수

IPC: A61K36/605

CPC classification number: A61K36/605

Abstract: 본 발명은 시토크롬 P450 효소로 전환된 오디추출물을 포함하는 염증성장질환의 예방 또는 치료용 약학조성물에 관한 것으로, 상세하게는 시토크롬 P450 효소로 전환된 오디추출물로 염증성장질환을 완화시키고, 비정상적으로 과도화된 활성면역세포를 조절하는 약학조성물에 관한 것이다. 본 발명을 통해, P450 효소전환된 오디추출물이 대장 조직 내에 점막의 면역조절 활성을 유도함으로써, 염증성장질환의 개선, 예방 또는 치료에 유용하게 활용될 수 있을 것으로 기대된다.

Abstract translation: 本发明涉及用于预防或治疗炎性肠病的药物组合物，其包含细胞色素P450酶转化的桑叶提取物，更具体地，涉及通过使用细胞色素P450酶减轻炎症性肠病和控制异常超活化的活化免疫细胞的药物组合物 转化桑树提取物。 通过本发明，P450酶转化的桑树提取物诱导大肠组织中粘膜的免疫控制活性，从而用于缓解，预防或治疗炎症性肠病。

公开(公告)号：KR101613835B1

公开(公告)日：2016-04-21

申请号：KR1020140077026

申请日：2014-06-24

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  윤철호 ,  장지훈 ,  이화연 ,  오승수

IPC: A61K36/605

Abstract: 본발명은시토크롬 P450 효소로전환된오디추출물을포함하는염증성장질환의예방또는치료용약학조성물에관한것으로, 상세하게는시토크롬 P450 효소로전환된오디추출물로염증성장질환을완화시키고, 비정상적으로과도화된활성면역세포를조절하는약학조성물에관한것이다. 본발명을통해, P450 효소전환된오디추출물이대장조직내에점막의면역조절활성을유도함으로써, 염증성장질환의개선, 예방또는치료에유용하게활용될수 있을것으로기대된다.

公开(公告)号：KR1020090090946A

公开(公告)日：2009-08-26

申请号：KR1020080016523

申请日：2008-02-22

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  김은미 ,  김동헌 ,  이은희 ,  최하림 ,  이화연

IPC: A61K39/395 ,  A61K38/00 ,  A61P35/00

CPC classification number: A61K39/39566 ,  A61K38/00 ,  Y10S514/885

Abstract: A composition for preventing and treating cervical cancer, which comprises lymphotoxin alpha/beta complex (LTalpha/beta) or lymphotoxin beta receptor (LTbeta-R) binding agent is provided to use an agent for preventing or treating cervical cancer by inducing the mucosa immune response. A composition for preventing and treating cervical cancer comprises limphotoxin alpha/beta complex or limphotoxin beta receptor binding agent as an active ingredient. The lymphotoxin alpha/beta complex is a surface lymphotoxin alpha/beta complex or recombinant soluble lymphotoxin alpha/beta complex. The lymphotoxin beta receptor is an antibody to lymphotoxin beta receptor. The antigen is polyclonal antibody or monoclonal antibody.

Abstract translation: 提供了一种用于预防和治疗宫颈癌的组合物，其包括淋巴毒素α/β复合物（LTα/β）或淋巴毒素β受体（LTbeta-R）结合剂，用于通过诱导粘膜免疫应答来预防或治疗宫颈癌 。 用于预防和治疗宫颈癌的组合物包含角光素α/β复合物或角叉松素β受体结合剂作为活性成分。 淋巴毒素α/β复合物是表面淋巴毒素α/β复合物或重组可溶性淋巴毒素α/β复合物。 淋巴毒素β受体是淋巴毒素β受体的抗体。 抗原是多克隆抗体或单克隆抗体。

公开(公告)号：KR100967623B1

公开(公告)日：2010-07-05

申请号：KR1020080016523

申请日：2008-02-22

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  김은미 ,  김동헌 ,  이은희 ,  최하림 ,  이화연

IPC: A61K39/395 ,  A61K38/00 ,  A61P35/00

Abstract: 본 발명은 유효성분으로서 림포톡신 α/β 복합체(Lymphotoxin α/β Complex, LTα/β) 또는 림포톡신 β 수용체(Lymphotoxin β receptor, LTβ-R) 결합제를 포함하는, 자궁경부암 예방 또는 치료용 조성물에 관한 것으로서, 점막면역 반응을 효과적으로 유도함으로써 자궁경부암의 예방 또는 치료제로 유용하게 이용될 수 있다.
림포톡신, 림포톡신 α/β 복합체, LTα/β, 림포톡신 β 수용체, LTβ-R, 점막면역, 인유두종바이러스, HPV, E6, 자궁경부암

公开(公告)号：KR1020090090944A

公开(公告)日：2009-08-26

申请号：KR1020080016520

申请日：2008-02-22

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  김은미 ,  이은희 ,  최하림 ,  박아름 ,  김일수 ,  이화연

IPC: A61K38/16 ,  A61K48/00 ,  A61P35/00

CPC classification number: A61K48/00 ,  A61K2039/585 ,  C12N9/12

Abstract: A method for screening therapeutic agent or suppressing tumor by regulating Axl signal is provided to increase the sensitivity of natural killer cell by the expression of LIGHT gene and induce apoptosis of tumor cell. A composition for suppressing tumor comprises LIGHT (lymphotoxin-like inducible protein that competes with glycoprotein D for binding herpesvirus entry mediator on T cells) (TNFSF14) or its activator as an active ingredient. The activator is Axl receptor tyrosine kinase or its ligand. The Axl ligand is an antibody to Axl antibody, gamma-carboxylated Gas-6(growth-arrest specific gene 6) or protein S. The tumor is lymphatic tumor. A method for screening agent for suppressing or treating tumor comprises: a step of adding a test compound to a LIGHT (TNFSF14) or its activator; and a step of researching the influence of the test compound on the expression or activation of LIGHT or its activator.

Abstract translation: 提供通过调节Axl信号筛选治疗剂或抑制肿瘤的方法，以通过LIGHT基因的表达增加自然杀伤细胞的敏感性并诱导肿瘤细胞凋亡。 用于抑制肿瘤的组合物包括LIGHT（与蛋白D竞争结合于T细胞上的疱疹病毒进入介导蛋白的竞争性淋巴毒素样诱导蛋白）（TNFSF14）或其活化剂作为活性成分。 活化剂是Axl受体酪氨酸激酶或其配体。 Axl配体是Ax1抗体，γ-羧化气体-6（生长停滞特异性基因6）或蛋白S的抗体。肿瘤是淋巴瘤。 用于抑制或治疗肿瘤的筛选剂的方法包括：将测试化合物加入到LIGHT（TNFSF14）或其活化剂中的步骤; 以及研究化合物对LIGHT或其活化剂表达或活化的影响的一个步骤。

公开(公告)号：KR1020090090918A

公开(公告)日：2009-08-26

申请号：KR1020080016480

申请日：2008-02-22

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  김은미 ,  이은희 ,  박아름 ,  이화연 ,  이자운 ,  조영미

IPC: A61K38/16 ,  A61K48/00 ,  A61P35/00

CPC classification number: A61K38/005 ,  A61K48/00

Abstract: A composition for preventing and treating cervical cancer, which contains AxL receptor tyrosine kinase inhibitor is provided to regulate the expression of human papilloma virus (HPV) type 16 E6 gene and reduce the proliferation and metastatic property of cancer cell. A composition for preventing and treating cervical cancer comprises an inhibitor of Axl receptor tyrosine kinase as an active ingredient. A method for screening an agent for preventing and treating cervical cancer comprises: a step of adding a test compound to the Axl receptor tyrosine kinase; and a step of researching the influence of the test sample to the expression or activation of Axl and selecting a compound which suppresses the expression or activation of Axl.

Abstract translation: 提供含有AxL受体酪氨酸激酶抑制剂的宫颈癌预防和治疗组合物，用于调节人乳头状瘤病毒（HPV）16型E6基因的表达，降低癌细胞的增殖和转移性。 用于预防和治疗宫颈癌的组合物包含Ax1受体酪氨酸激酶的抑制剂作为活性成分。 用于筛选预防和治疗宫颈癌的药剂的方法包括：将测试化合物加入到Ax1受体酪氨酸激酶中的步骤; 研究测试样品对Axl的表达或活化的影响并选择抑制Ax1表达或激活的化合物的步骤。